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Background: Advanced hepatocellular carcinoma (HCC) not
amenable to local therapies has limited chances of cure and has
a poor prognosis. Sorafenib is a multikinase inhibitor with proven
activity in advanced HCC. Octreotide is already used in this set-
ting with conflicting but usually interesting results.
Methods: An original schedule with sorafenib and long-acting
octreotide is currently tested in advanced HCC enrolled from dif-
ferent institutions. Sorafenib is administered at a dosage of
400 mg/daily for 28 d with a following week of rest. Ten days after
starting sorafenib, long acting octreotide is administered at a dose
of 40 mg with monthly scheduled administrations. Objectives of
this study are the evaluation of activity and potential toxicity of
the treatment. Tumor response is assessed bimontly.
Results:At the date of 28 April 2008, 57 patientswere considered
for study entry and 42 were enrolled (sex: 33M/9F; age range: 57–80
years; HCV: 26 patients, HBV: 10 patients, HCV + HBV: 1 patient;
unknown etiology: 5 patients; childA/B: 31/11). Patients naı¨ve from
other therapieswere 19, whilst all the otherswere previously trea-
tedwith local and/or systemic treatments. Threepatientswere not
evaluable because of premature treatment stopping caused by
diarrhoea grade 3. Twenty-four patients were evaluated until
now. Among 12 patients evaluable after 2 months of therapy, we
registered 1 minimal response, 3 stable disease and 8 disease pro-
gression. Among 8 patients evaluable after 4 months, we reported
5 stable disease and 3 disease progression. Among 4 patients
evaluable after 6 months, we reported 1 minimal response and 3
stable disease. Treatment was generally well tolerated apart from
haemorrhoidal bleeding (2 patients), skin toxicity grade 2 and
grade 3 in 2 patients, respectively, hypertension in 3 patients.
Conclusions: The association of sorafenib and long acting octre-
otide appears feasible in advanced hepatocellular carcinomas not
susceptible of local therapies. Longer follow-up of this study is
needed to evaluate clinical activity of this schedule.
doi:10.1016/j.ejcsup.2008.06.039
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Background: FOLFOX regimen represents a standard first
line therapy for ACRC. Recent studies observed that tri-weekly
XELOX administration is characterised by effectiveness and toler-
ance similar to FOLFOX 4 infusional schedule. This phase II mul-
ticenter study of the Gruppo Oncologcio dell’Italia Meridionale
(GOIM) started to evaluate the activity and the toxicity of bi-
weekly administration of capecitabine + oxaliplatin in ACRC
patients.
Materials and methods: Thirty-two advanced colorectal cancer
pts with measurable disease, ECOG PS 6 2, age 18–75 years (yrs)
were enrolled. The schedule of treatment was as follows: oxalipl-
atin at 100 mg/mq i.v. on day 1 and capecitabine at 2000 mg/mq
p.o. in a two daily administration from days 1 to 7, every 2 weeks.
The recist and NCI criteria were employed to determine the activ-
ity and the toxicity of this combination, respectively.
Results: At present, 32 patients have been enrolled and up to
now 29 of them are evaluable for activity and toxicity. The main
characteristics were: sex (M/F) 23/9, median age 70 yrs (range
54–75), median PS 0, main sites of disease: liver 26 (81%),
lymph-nodes 9 (28%) and lung 4 (12%). One CR (3%) and 12 PR
(42%), 8 SD (27%) and 8 PD (27%) were observed. The main toxicity
rate (G1–2 versus G3–4) were: thrombocytopenia 44/6, anaemia
41/0, nausea/vomiting 28/0, diarrhoea 22/0, neurotoxicity 50/0
and asthenia 16/3.
Conclusions: These preliminary data show that the bi-weekly
administration of capecitabine + oxaliplatin is active and well tol-
erated by ACRC patients. This study is still ongoing.
doi:10.1016/j.ejcsup.2008.06.040
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Background: Irinotecan (Cpt-11) plus fluorouracil (Fu) modu-
lated by folinic acid (Fa) (folfiri regimen) is one of the standard
first-line treatment in advanced colorectal cancer (ACC). The oral
fluoropyrimidine xeloda (Xel) is equivalent in terms of efficacy
and demonstrated a better safety profile than bolus Fu–Fa.
Besides Xel can replace Fu continuous infusion. Also the combi-
nation of Cpt-11 plus Xel (xeliri regimen) demonstrated to be
active as a first-line treatment in ACC patients. So the GOIM
started a randomised multicenter phase II trial aiming to com-
pare the activity and safety of folfiri and xeliri in this setting.
Methods: Untreated patients with histologically confirmed
diagnosis of colorectal cancer entered into the trial if they satis-
fied the following inclusion criteria: presence of measurable dis-
ease (recist criteria), age > 18 years, performance status < 2 (Ecog
scale), adequate bone marrow reserve and renal and hepatic
function, informed written consent. The enrolled patients were
randomised 1:2 to receive arm A: Cpt-11 at 180 mg/m2 on day 1,
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FA at 100 mg/m2 as 2 h infusion on days 1–2, FU at 400 mg/m2 as
bolus on days 1–2 plus FU at 600 mg/m2 as 22 h infusion on days
1–2 (folfiri) every 2 weeks, or arm B: Cpt-11 at 250 mg/m2 on day 1
and xeloda 2000 mg/m2 for 14 days (xeliri) every 3 weeks.
Results: Up to now 91 patients have been enrolled: 54 are evalu-
able for activity and toxicity (A/B: 20/34). The main characteristics
of the evaluable patients are (A/B): median PS: 0/0; sites of dis-
ease: liver 12/26, lung 7/15, lymph-nodes 1/8, others 3/4. Among
the evaluable patients we observed the following responses (A/
B) CR: 1/0 (5/0%), PR: 4/18 (20/53%), SD: 11/11 (55/32%) and PRO:
4/5 (20/15%) for an ORR of 25% and 53%, respectively. Grades 3–4
haematologic toxicity (NCI criteria) were: neutropenia 15/21%
and anaemia 5/3% whilst the main non haematologic side effect
was diarrhoea observed in 5/18%, respectively.
Conclusions: Our preliminary results do not permit any
definitive conclusion regard the activity of the two combinations.
The toxicity profile of xeliri is similar to those of previous
studies.
doi:10.1016/j.ejcsup.2008.06.041
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Background: The addition of bevacizumab (BEV) to irinotecan
(CPT-11) plus bolus fluorouracil (FU) and folinic acid (FA) (IFL regi-
men) demonstrated to bemore active andmore effective than che-
motherapy alone in a randomised phase III trial. However IFL is
considered more toxic than FOLFIRI regimen. So we started a
phase II trial to evaluate the activity and the safety of the combina-
tion of BEV plus FOLFIRI as first-line therapy in ACC patients (pts).
Methods: Untreated pts with histologically confirmed diagnosis
of colorectal cancer entered into the trial if they satisfied the fol-
lowing main inclusion criteria: presence of measurable disease,
age > 18 years, performance status 6 2 (ECOG scale), adequate
bone marrow reserve and renal and hepatic function, informed
written consent. An history of cardiovascular disease, thrombo-
embolic events and/or coagulative disorders were considered as
exclusion criteria.
The enrolled pts were treated with CPT-11 at 180 mg/m2 on
day 1, FA at 100 mg/m2 as 2 h infusion on days 1–2, FU at
400 mg/m2 as bolus on days 1–2 and FU at 600 mg/m2 as 22 h infu-
sion on days 1–2 (FOLFIRI) plus BEV at the dosage of 5 mg/kg on
day 1, every twoweeks. A maximum of 12 cycles of chemotherapy
was planned and a maintenance with BEV for 6 months was per-
mitted. The evaluation of the activity (recist criteria) was per-
formed every four cycles.
Results: Up to now 72 pts have been enrolled and 61 are evalu-
able for activity and safety (eleven pts are too early). The main
characteristics of the evaluable pts were M/F: 32/29; median PS:
0 (range 0–2); median age 61 (range 33–73); primary site (colon/
rectum): 40/21; main sites of disease: liver 45, lung 16, lymph-
nodes 15, others 6; single site: 39 and multiple sites: 22.
Three CR (5%) and 25 PR (41%) were observed for an ORR of 46%;
26 pts had SD (43%) for an overall TGCR of 89%. Only 7 PRO (11%)
were observed. The response rate according to site were: liver
21/45 (46.6%), lung 8/16 (50%). The only grades 3–4 toxicity (NCI cri-
teria) were neutropenia 10% and thrombocytopenia 2%. Ten pts
(16%) had hypertension but only one was uncontrolled by medical
therapy and interrupted the study. One pts had epistaxis.
Conclusions: Our results indicate that the addition of BEV to
FOLFIRI regimen is an active and well tolerated first-line treat-
ment for ACC pts. Final data will be available for the meeting.
doi:10.1016/j.ejcsup.2008.06.042
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Background: Radiochemotherapy of anal carcinoma is an organ
sparing approach with a high curative potential.
Patients and methods: Between August 1999 and June 2007, 18
patients were treated with external radiation therapy (RT) and
concomitant chemotherapy (CT). The main characteristics of
patients were: histology: 14 squamous carcinoma, 2 basaloid, 1
adenocarcinoma, 1 undifferentiated carcinoma; stage (2001 UICC
classification): II 7 cases, III A 9, III B 2; age: median 61 year, range
33–79; sex (F/M): 10/8. RTwas delivered at the whole pelvis with a
four-field box technique followed by a boost at the primary
tumour. The median dose of RT at the whole pelvis and at the pri-
mary tumours was 45 Gy and 55 Gy, respectively. CTwas carried
out during the first and last four days of RTwith continuous infu-
sion of 5-fluorouracil (1000 mg/m2/day) plus bolus mitomycin C
(10 mg/m2 on day 1) in 16 patients or cisplatin (100 mg/m2) in 2.
After a rest period of 4-6 weeks two courses of cisplatin plus 5-
Fluorouracil was delivered in 4 patients with locoregional
advanced disease.
Results: CR were observed in 8 patients (44%), PR in 4 (22%), SD
in 4, and PD in 2. Local recurrences occurred in 4 patients previ-
ously obtaining RC (1/8), RP (2/4), SD (1/4) and 2 of them were res-
cued by conservative surgery. Distant metastases occurred in two
cases and inguinal failure in one. The median duration of
response was 12 months (3–62) and the sphincter preservation
rate was 90% (16 patients). Temporary interrumption of the treat-
ment as a result of acute toxicity (gastrointestinal) was necessary
in 3 patients. With a median follow up of 17 months (range 5–57),
10 patients are alive and 9 disease-free. Eight patients died due to
a progressive disease (locoregional failure in 5 patients, liver
metastases in 2, lung metastases in 1).
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